EASD 2026 at a gance
At EASD 2026, where will competition in diabetes and metabolic health shift next? The EASD 2026 agenda points to a widening competitive field across next-generation incretin therapies, amylin combinations, earlier type 1 diabetes (T1D) intervention, integrated diabetes technology and AI-enabled clinical decision support.
📅 Build your schedule around the topics that matter most.
📥 Download the EASD 2026_Preview_by_LucidQuest
Key Diabetes and Metabolic Health Trends at EASD 2026
Next-Generation Incretin Therapies: Retatrutide, CagriSema and Zenagamtide
Retatrutide, CagriSema and zenagamtide will put multi-receptor and amylin-based treatment strategies firmly in focus, highlighting emerging approaches in diabetes and metabolic health.
Beyond Glycaemic Control: Cardiovascular, Renal and Liver Outcomes
Cardiovascular, renal and liver outcomes will feature prominently as companies increasingly position diabetes within a broader cardiometabolic treatment model.
Integrated Diabetes Technology: CGM and Automated Insulin Delivery
Continuous glucose monitoring (CGM), automated insulin delivery, dual sensing and connected technologies may move further beyond monitoring toward treatment optimisation.
Competitor and Industry Signals at EASD 2026
Novo Nordisk: Semaglutide, CagriSema and Amylin-Based Therapies
Semaglutide, CagriSema, cagrilintide and zenagamtide will span established incretin care and Novo Nordisk’s expanding amylin-focused pipeline.
Eli Lilly: Cardiometabolic Therapies and Once-Weekly Insulin Efsitora Alfa
Cardiometabolic therapies, emerging oral approaches and once-weekly insulin efsitora alfa will highlight both pipeline innovation and treatment convenience.
Sanofi: Early Type 1 Diabetes Detection and Teplizumab
Early T1D detection, autoantibody testing and teplizumab will focus attention on building clinical pathways from identification through disease-modifying treatment.
Emerging Diabetes and Obesity Pipeline: New Competitive Entrants
Olatorepatide, HRS-4729, SHR-3167, CT-996, BGM0504, MTX-101 and XTL6001 add further competitive depth across obesity and diabetes.
Artificial Intelligence and Machine Learning at EASD 2026
AI-Enabled Diabetes Care: Digital Twins, CGM Phenotyping and Risk Prediction
Agentic AI, digital twins, CGM phenotyping, multimodal models and large language model (LLM)-based risk prediction will feature across screening, treatment decisions and remote care.
AI Clinical Decision Support and Personalised Diabetes Treatment
The strategic question is whether AI-derived insights can become meaningfully integrated with CGM, automated insulin delivery and personalised treatment pathways.
What We Are Watching After EASD 2026
- Whether combination therapies can extend benefits across glycaemic control, weight management and cardiorenal outcomes.
- Whether diabetes technology demonstrates broader clinical value beyond monitoring.
- Whether earlier detection, AI-driven risk stratification and personalised care begin to change routine clinical pathways.
Download the EADV 2026 Preview Report
Download LucidQuest’s EADV 2026 Preview for deeper analysis of emerging diabetes therapies, metabolic health developments and competitive signals.
📅 Build your schedule around the sessions that matter most.
📥 Download the EASD 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
